Randomisierte kontrollierte Studien und Real-World-Evidence in der Marktzulassung und Überwachung von Hochrisikoprodukten – Das Beispiel Paclitaxel

Randomized controlled trials and real-world evidence for the market access and surveillance of high-risk products—the example of paclitaxel

A PAVK to this article was published on 27 November 2020

Zusammenfassung

In den Jahren 2018 und 2020 haben zwei Metaanalysen zu kumulativen Ergebnissen von randomisierten und kontrollierten Studien eine erhöhte Sterblichkeit nach der Anwendung Paclitaxel-beschichteter Stents bzw. Ballons in den Gefäßen der unteren Extremitäten berichtet. Im Anschluss daran entwickelte sich eine angeregte globale Diskussion über die Validität dieser Assoziation, wobei die Ergebnisse zahlreicher Beobachtungsstudien mit klinischen und administrativen Registerdaten die Anwendungssicherheit beschichteter Medizinprodukte nahelegten. Dieser Artikel fasst die Entwicklung und Verbreitung Paclitaxel-beschichteter Ballons und Stents zur Behandlung der peripheren arteriellen Verschlusskrankheit in der klinischen Praxis, in Studien und in Leitlinien zusammen. Hierbei wird ein besonderer Fokus auf die neue Medizinprodukteregulation der Europäischen Union gelegt, die weitreichende Implikationen für die Marktzulassung und Überwachung von Hochrisikomedizinprodukten hat.

Abstract

In 2018 and 2020, two meta-analyses using summary-level data from randomized controlled trials reported worse mortality following the application of paclitaxel-coated stents and balloons in femoropopliteal and crural arteries. These results initiated a heated global discussion concerning the validity of this association, while various observational studies using clinical and administrative registries proved the safety of coated devices. This article aimed to summarize the development and adoption of paclitaxel-coated balloons and stents for the treatment of peripheral arterial occlusive disease in clinical practice, research, and practice guidelines. It especially focusses on the European Unionʼs medical device regulation, which has far-reaching implications for the market approval and monitoring of high-risk medical devices.

This is a preview of subscription content, access via your institution.

Abb. 1

Literatur

  1. 1.

    Aboyans V, Ricco JB, Bartelink MEL et al (2018) Editor’s choice – 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg 55:305–368

    Article  Google Scholar 

  2. 2.

    Anonymous (2019) Correction to: Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery 5‑year results of the Zilver PTX randomized trial. Circulation 139:e42

    Google Scholar 

  3. 3.

    Lawall et al (2016) S3-Leitlinie PAVK – Diagnostik, Therapie und Nachsorge der peripheren arteriellen Verschlusskrankheit. Vasa 45(Suppl 95):1–100

    Google Scholar 

  4. 4.

    Behrendt CA, Peters F, Mani K (2020) The swinging pendulum of evidence: Is there a reality behind results from randomised trials and real world data? Lessons learned from the paclitaxel debate. Eur J Vasc Endovasc Surg 59:510–511

    Article  Google Scholar 

  5. 5.

    Behrendt CA, Sedrakyan A, Peters F et al (2020) Editor’s choice—Long term survival after femoropopliteal artery revascularisation with paclitaxel coated devices: a propensity score matched cohort analysis. Eur J Vasc Endovasc Surg 59:587–596

    Article  Google Scholar 

  6. 6.

    Behrendt CA, Sigvant B, Kuchenbecker J et al (2020) International variations and gender disparities in the treatment of peripheral arterial occlusive disease—a report from VASCUNET and the International Consortium of Vascular Registries. Eur J Vasc Endovasc Surg. https://doi.org/10.1016/j.ejvs.2020.08.027

    Article  PubMed  Google Scholar 

  7. 7.

    Bertges DJ, Sedrakyan A, Sun T et al (2020) Mortality after paclitaxel coated balloon angioplasty and stenting of superficial femoral and popliteal artery in the vascular quality initiative. Circ Cardiovasc Interv 13:e8528

    Article  Google Scholar 

  8. 8.

    Böhme T, Noory E, Beschorner U et al (In Press) Evaluation of mortality following paclitaxel drug-coated balloon angioplasty of femoropopliteal lesions in patients with ulcerations and gangrene—a single center experience. Vasa

  9. 9.

    Columbo JA, Martinez-Camblor P, Mackenzie TA et al (2018) Comparing long-term mortality after carotid endarterectomy vs carotid stenting using a novel instrumental variable method for risk adjustment in observational time-to-event data. JAMA Netw Open 1:e181676

    Article  Google Scholar 

  10. 10.

    Conte MS, Bradbury AW, Kolh P et al (2019) Global vascular guidelines on the management of chronic limb-threatening ischemia. Eur J Vasc Endovasc Surg 58:S1–S109.e133

    Article  Google Scholar 

  11. 11.

    Dake MD, Ansel GM, Jaff MR et al (2016) Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5‑year results of the Zilver PTX randomized trial. Circulation 133:1472–1483 (discussion 1483)

    CAS  Article  Google Scholar 

  12. 12.

    Dinh K, Gomes ML, Thomas SD et al (2020) Mortality after paclitaxel-coated device use in patients with chronic limb-threatening ischemia: a systematic review and meta-analysis of randomized controlled trials. J Endovasc Ther 27:175–185

    Article  Google Scholar 

  13. 13.

    Feldman DN, Armstrong EJ, Aronow HD et al (2018) SCAI consensus guidelines for device selection in femoral-popliteal arterial interventions. Catheter Cardiovasc Interv 92:124–140

    Article  Google Scholar 

  14. 14.

    Frank U, Nikol S, Belch J et al (2019) ESVM guideline on peripheral arterial disease. Vasa 48:1–79

    Article  Google Scholar 

  15. 15.

    Gerhard-Herman MD, Gornik HL, Barrett C et al (2017) 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol 69:e71–e126

    Article  Google Scholar 

  16. 16.

    Grube E, Schofer J, Hauptmann KE et al (2010) A novel paclitaxel-eluting stent with an ultrathin abluminal biodegradable polymer. JACC Cardiovasc Interv 3:431–438

    Article  Google Scholar 

  17. 17.

    Heidemann F, Peters F, Kuchenbecker J et al (2020) Long term outcomes after revascularisations below the knee with paclitaxel coated devices: a propensity score matched cohort analysis. Eur J Vasc Endovasc Surg. https://doi.org/10.1016/j.ejvs.2020.06.033

    Article  PubMed  Google Scholar 

  18. 18.

    Katsanos K, Spiliopoulos S, Kitrou P et al (2018) Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 7:e11245

    Article  Google Scholar 

  19. 19.

    Katsanos K, Spiliopoulos S, Kitrou P et al (2020) Risk of death and amputation with use of paclitaxel-coated balloons in the infrapopliteal arteries for treatment of critical limb ischemia: a systematic review and meta-analysis of randomized controlled trials. J Vasc Interv Radiol 31:202–212

    Article  Google Scholar 

  20. 20.

    Krawisz A, Secemsky EA (2019) Real-world data collection regarding paclitaxel treatment. Endovasc Today 18:72–76

    Google Scholar 

  21. 21.

    Kreutzburg T, Peters F, Riess HC et al (2020) Editor’s choice—Comorbidity patterns among patients with peripheral arterial occlusive disease in Germany: a trend analysis of health insurance claims data. Eur J Vasc Endovasc Surg 59:59–66

    Article  Google Scholar 

  22. 22.

    Kuno T, Ueyama H, Mikami T et al (2020) Mortality in patients undergoing revascularization with paclitaxel eluting devices for infrainguinal peripheral artery disease: insights from a network meta-analysis of randomized trials. Catheter Cardiovasc Interv. https://doi.org/10.1002/ccd.29125

    Article  PubMed  Google Scholar 

  23. 23.

    Lansky AJ, Costa RA, Mintz GS et al (2004) Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions. Circulation 109:1948–1954

    CAS  Article  Google Scholar 

  24. 24.

    Liistro F, Porto I, Angioli P et al (2013) Drug-eluting balloon in peripheral intervention for below the knee angioplasty evaluation (DEBATE-BTK): a randomized trial in diabetic patients with critical limb ischemia. Circulation 128:615–621

    CAS  Article  Google Scholar 

  25. 25.

    Mills JL, Conte MS, Murad MH (2019) Critical review and evidence implications of paclitaxel drug-eluting balloons and stents in peripheral artery disease. J Vasc Surg 70:3–7

    Article  Google Scholar 

  26. 26.

    Mohapatra A, Bertges DJ, Madigan MC et al (2018) Nationwide trends in drug-coated balloon and drug-eluting stent utilization in the femoropopliteal arteries. J Vasc Surg 68:e15–e16

    Article  Google Scholar 

  27. 27.

    Moliterno DJ (2005) Healing Achilles—sirolimus versus paclitaxel. N Engl J Med 353:724–727

    CAS  Article  Google Scholar 

  28. 28.

    Mustapha JA, Brodmann M, Geraghty PJ et al (2019) Drug-coated vs uncoated percutaneous transluminal angioplasty in infrapopliteal arteries: six-month results of the Lutonix BTK trial. J Invasive Cardiol 31:205–211

    PubMed  Google Scholar 

  29. 29.

    Ouriel K, Adelman MA, Rosenfield K et al (2019) Safety of paclitaxel-coated balloon angioplasty for femoropopliteal peripheral artery disease. JACC Cardiovasc Interv 12:2515–2524

    Article  Google Scholar 

  30. 30.

    Peters F, Kreutzburg T, Kuchenbecker J et al (2020) Behandlungsqualität in der operativ-interventionellen Gefäßmedizin – was können Routinedaten der Krankenkassen leisten? Gefässchirurgie. https://doi.org/10.1007/s00772-020-00664-x

    Article  Google Scholar 

  31. 31.

    Rissanen TT, Uskela S, Eränen J et al (2019) Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial. Lancet 394:230–239

    Article  Google Scholar 

  32. 32.

    Rocha-Singh KJ, Duval S, Jaff MR et al (2020) Mortality and paclitaxel-coated devices. Circulation 141:1859–1869

    Article  Google Scholar 

  33. 33.

    Saratzis A, Lea T, Yap T et al (2020) Paclitaxel and mortality following peripheral angioplasty: an adjusted and case matched multicentre analysis. Eur J Vasc Endovasc Surg 60:220–229

    Article  Google Scholar 

  34. 34.

    Scheller B, Hehrlein C, Bocksch W et al (2006) Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med 355:2113–2124

    CAS  Article  Google Scholar 

  35. 35.

    Schneider PA, Laird JR, Doros G et al (2019) Mortality not correlated with paclitaxel exposure: an independent patient-level meta-analysis of a drug-coated balloon. J Am Coll Cardiol 73:2550–2563

    Article  Google Scholar 

  36. 36.

    Schneider PA, Laird JR, Tepe G et al (2018) Treatment effect of drug-coated balloons is durable to 3 years in the femoropopliteal arteries: long-term results of the IN.PACT SFA randomized trial. Circ Cardiovasc Interv 11:e5891

    PubMed  PubMed Central  Google Scholar 

  37. 37.

    Secemsky EA, Kundi H, Weinberg I et al (2019) Association of survival with femoropopliteal artery revascularization with drug-coated devices. JAMA Cardiol 4:332–340

    Article  Google Scholar 

  38. 38.

    Sedrakyan A, Campbell B, Merino JG et al (2016) IDEAL-D: a rational framework for evaluating and regulating the use of medical devices. BMJ 353:i2372

    Article  Google Scholar 

  39. 39.

    Tepe G, Schnorr B, Albrecht T et al (2015) Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5‑year follow-up of the THUNDER trial. JACC Cardiovasc Interv 8:102–108

    Article  Google Scholar 

  40. 40.

    Zhang X, Xie J, Li G, Chen Q, Xu B (2014) Head-to-head comparison of sirolimus-eluting stents versus paclitaxel-eluting stents in patients undergoing percutaneous coronary intervention: a meta-analysis of 76 studies. PLoS One. https://doi.org/10.1371/journal.pone.0097934

    Article  PubMed  PubMed Central  Google Scholar 

  41. 41.

    Yang C‑P, Horwitz S (2017) Taxol®: the first microtubule stabilizing agent. Int J Mol Sci 18(8):1733

    Article  Google Scholar 

  42. 42.

    Zeller T, Baumgartner I, Scheinert D et al (2014) Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial. J Am Coll Cardiol 64:1568–1576

    Article  Google Scholar 

  43. 43.

    Zeller T, Beschorner U, Pilger E et al (2015) Paclitaxel-coated balloon in infrapopliteal arteries: 12-month results from the BIOLUX P‑II randomized trial (BIOTRONIK’S-first in man study of the Passeo-18 LUX drug releasing PTA balloon catheter vs. the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularization of infrapopliteal arteries). JACC Cardiovasc Interv 8:1614–1622

    Article  Google Scholar 

  44. 44.

    Zeller T, Noory E, Beschorner U et al (2019) Outstanding effectiveness of paclitaxel-based technologies for the treatment of femoropopliteal artery occlusive disease on the potential expense of increased late all-cause mortality? No reason to panic. Vasa 48:109–111

    Article  Google Scholar 

Download references

Funding

Diese Arbeit ist durch Mittel der RABATT-Studie gefördert worden (Innovationsfonds des Gemeinsamen Bundesausschusses, Förderkennzeichen 01VSF18035, PI: CAB).

Author information

Affiliations

Authors

Consortia

Corresponding author

Correspondence to Priv.-Doz. Dr. C.-A. Behrendt.

Ethics declarations

Interessenkonflikt

C.-A. Behrendt ist Vorsitzender des Medical Device Epidemiology Network (MDEpiNet) Verband Deutschland e. V. i.G. und beratend tätig im wissenschaftlichen Beirat einer akkreditierten benannten Stelle (MEDCERT). U. Rother, G. Rümenapf, C. Uhl, H. Görtz und D. Böckler geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Behrendt, CA., Rother, U., Rümenapf, G. et al. Randomisierte kontrollierte Studien und Real-World-Evidence in der Marktzulassung und Überwachung von Hochrisikoprodukten – Das Beispiel Paclitaxel. Gefässchirurgie 26, 110–117 (2021). https://doi.org/10.1007/s00772-020-00713-5

Download citation

Schlüsselwörter

  • Routinedaten
  • Versorgungsforschung
  • Validität
  • Qualitätsindikatoren
  • Administrative Daten

Keywords

  • Routine data
  • Health-care research
  • Validity
  • Quality indicators
  • Administrative data